





# EMPOWER

April 2024









This presentation contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Such forward-looking statements are based on assumptions known to management at this time and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Financing may not be completed on the terms expected or at all, and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.





At Empower we believe all people should have access to an integrated healthcare experience

## **EPW Curesearch**

Patient-focused with the goal of impacting lives and the future of healthcare outcomes through clinical trials and the management of research sites



### Best-in-Class Research and Clinical Trials Services

#### **Growth Plan**

- Leveraging Dallas & Los Angeles healthcare markets for clinical trials and research as a Site Management Organization (SMO)
- Six sites activated with eleven Principal Investigators (PI) under contract
- Currently eight trial applications underway with two trials awarded

#### **Immediate Opportunities**

- Commencement of clinical studies focused on Neurology, Cardiology, Pulmonology, Dermatology, Rheumatology, Gastroenterology, Oncology
- Additional Sites under negotiation in California, Texas, Pennsylvania





The Infrastructure: Technology Layers | Our tech priorities include patient information management, information security, and clinical trial management solutions

#### **Tech Roadmap**

## **Patient Information** Management

## Information Security



## **Clinical Trial** Management



- **Flectronic Medical Records**
- Patient portals
- Decentralized clinical trials mgmt.
- Remote patient monitoring

- Patient focused technology path
- Electronic health information security
- Technology leadership in research
- Leveraging technology to improve research outcomes

- Clinical decision support systems
- General clinic management
- SMO site operations
- Strong Sponsor and CRO support

#### ARTIFICIAL INTELLIGENCE FOR RESEARCH PROTOCOLS





#### KPI's and Portfolio Management

- Empower is currently targeting phase 2 & phase 3 interventional drug clinical trials in across multiple disease categories
- The company has an active Pulmonary trial as well as applications submitted for Neurology, Cardiology, Pulmonology, Dermatology, Rheumatology, Gastroenterology, Oncology
- Empower is currently recruiting patients in the phase III Pulmonary trial with active operations

#### **Current Operations**

Summary	Active	Signed	Pending
Pl's	1	11	30
Practices	1	5	8
Sites	2	6	10
Studies	1	1	17
Patients			6

#### **Trial Sponsors**

Sponsor List	Active	Awarded	<b>Application</b>	Pending
Sanofi	1	2	2	5
Eli Lilly			2	
Amgen			1	
Abbvie				1
AstraZeneca			2	
Otsuka				1
PPD			1	1
Cerevel				1
UCB				1
EMD Serono				1
Totals	1	2	8	11





#### **STEVEN MCAULEY**

#### **CEO & CHAIRMAN**

A successful leader with extensive experience in technology, financial services and capital markets.

- CEO at Xpel Technologies (NASDAQ:XPEL)
- SVP at Penske Automotive (NYSE:PAG)
- CEO at GE Capital Fleet Services UK



#### **ALEXIS WUKICH**

#### **BOARD MEMBER**

More than 15 years of healthcare, legal and talent management experience.

- Executive VP and Corporate Counsel at Danan Healthcare Consulting Group
- Managing Director at Arriba International Staffing Services
- Quest Healthcare Development



#### **ANDREJS BUNKSE**

#### **BOARD MEMBER**

An attorney and entrepreneur with decades of experience quiding companies in heavily regulated industries.

- CEO of Endurance Strategies Group
- General Counsel at Redflex Traffic Systems (ASX:RDF)
- General Counsel at GameTech International (NASDAQ:GMTC)



DR. TYLER COUPAL, MD FRCPC FABR

#### MEDICAL DIRECTOR

- Radiologist for Richmond, Burnaby and Delta Hospitals
- McMaster University (MD), University of British Columbia

(FRCPC), Harvard University (FABR, Diagnostic and Interventional Musculoskeletal Radiology)

## The Winning Formula.

#### **TALENT**



Proven team with traction in leading high growth companies, capital markets and healthcare. Partnerships with leading doctors in Neurology, Cardiology, Pulmonology, Dermatology, Rheumatology, Gastroenterology, Oncology

#### **HIGH GROWTH MARKET**




Soaring demand for research & clinical trial services. Breakthrough technology and artificial intelligence have transformed the way research and drug discovery is conducted

#### TIMING



Diseases are becoming more complex, requiring innovative approaches and therapies. Global health challenges, regulatory changes, and advancements in technology are driving the need for more research and clinical trials



Empowerclinics.com | Info@empowerclinics.com

